This I not good for patients or the U.S. biotech industry. Hard to invest when you run the study aligned with the FDA, hit the primary endpoint, and then have to deal with this…..
We hope the FDA will stop torpedoing promising drugs, but the story of biotech firm Sydnexis’s battle with the bureaucracy suggests more obstacles ahead.
https://t.co/sLI9TDKvIk
Led by former Trump HHS official Brett Giroir, Altesa raised $75M to advance its oral COPD drug into a Phase 2b trial aimed at preventing serious flare-ups. https://t.co/LUElDQGtrQ
We’ve entered into an agreement to acquire Vicebio. This brings an early-stage combination vaccine candidate for RSV and hMPV, both respiratory viruses, and expands capabilities in vaccine design and development with ‘Molecular Clamp’ technology. Read more ⬇️
The CCP steals a lot of our IP, including defense and AI breakthroughs—but now it’s aiming for a whole sector: biotech.
Their unethical actions are already decimating US biotech investment; we face a serious crisis.
Here’s what’s on the line—and how we can fight back. 🧵
If we fund these drugs, why are we getting charged so much for them?
Do we get a licensing fee, royalty or equity in the companies that make them?
Educate me please
It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to?
We need to cap these costs for patients and #fixinsurance.
Please share and help, @MariahCarey , @jessicaalba, @Eminem, @Pink, @JeromeBettis36!